Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus TRIMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus TRIMOX.
LAROTID vs TRIMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours depending on infection severity.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1-1.5 hours (normal renal function); in renal impairment (CrCl <10 mL/min), extends to 6-20 hours, requiring dose adjustment.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 50-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minimal, <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic